Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients

Litao Xu; Shulin Yu; Liping Zhuang; Peng Wang; Yehua Shen; Junhua Lin; Zhiqiang Meng

doi:10.18632/oncotarget.16865

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients

Litao Xu, Shulin Yu, Liping Zhuang, Peng Wang, Yehua Shen, Junhua Lin and Zhiqiang Meng _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:34954-34960. https://doi.org/10.18632/oncotarget.16865

Metrics: PDF 1901 views | HTML 2843 views | ?

Abstract

Litao Xu1,2,*, Shulin Yu1,2,*, Liping Zhuang1,2,*, Peng Wang1,2, Yehua Shen1,2, Junhua Lin1,2, Zhiqiang Meng1,2

1Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

*These authors contributed equally to this work and should be considered co-first authors

Correspondence to:

Zhiqiang Meng, email: [email protected], [email protected]

Keywords: hepatocellular carcinoma, systemic inflammation response index, local therapy, systemic therapy, survival

Received: August 01, 2016 Accepted: March 24, 2017 Published: April 05, 2017

ABSTRACT

The systemic inflammation response index (SIRI) is a useful tool for predicting prognosis in some types of cancer. In this retrospective study, we evaluated the efficacy of SIRI in predicting overall survival in hepatocellular carcinoma (HCC) patients following local or systemic therapy. A cutoff value of 1.05 was identified for SIRI using ROC analysis in a training patient cohort. In the validation cohort, survival analysis revealed that median overall survival was longer in HCC patients with SIRI scores < 1.05 than in those with scores ≥ 1.05. Cox analysis of the validation cohort demonstrated that SIRI was associated with overall survival and was more predictive of overall survival that the AFP level or Child-Pugh score. However, SIRI and Barcelona Clinic Liver Cancer (BCLC) stage were equally effective for predicting survival. In addition, HCC patients with BCLC stage C had higher SIRI scores and poorer overall survival. SIRI also correlated with liver function parameters. Thus SIRI may be a convenient, low cost and reliable tumor marker for predicting prognosis in HCC patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16865

Publication Alerts

Research Papers:

Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients

Abstract